Navigation Links
Avoiding False Positives Key Priority in Cardiac Safety Studies
Date:5/4/2009

Pharmaceutical Companies Recognizing Risks with Traditional Cardiac Safety Approaches

Rochester, NY (PRWEB) May 4, 2009 -- iCardiac Technologies, Inc., a leading innovator in advanced cardiac safety biomarkers and automated QT analysis, today announced the results of its online survey of pharmaceutical companies, biotechnology companies and industry consultants. When asked about the key priorities for cardiac safety studies, avoiding false positives was selected as the single highest priority with 46% of survey respondents ranking it as the most important attribute.

"The results of the survey are consistent with the growing recognition that conventional cardiac safety studies have significant limitations," said Sasha Latypova, Executive Vice President of iCardiac Technologies. "Interest in avoiding both false positives as well as false negatives is especially acute in today's environment as many drug developers are re-prioritizing their portfolios and focusing on fewer compounds."

As drug developers and regulators have gained extensive experience with cardiac safety studies since the introduction of the E14 guidance in 2005, it is now evident that while progress has been made, there are still many issues to be addressed in cardiac safety. Specifically, techniques that can more accurately and cost-effectively assess the effect of a novel drug on cardiac repolarization are needed. It is commonly estimated that false positives and false negatives may impact as many as 10% to 25% of drugs in portfolios at Phase I and beyond because of current limitations of conventional techniques used in cardiac safety studies.

In addition to the desire to avoid false positives, 27% of the respondents selected the quality of the expert report as the most important criteria while 12% selected cost effective study design and 6% rapid study execution. A total of 419 pharmaceutical and biotechnology professionals responded to the survey which was conducted between February 25th and April 21st of 2009.

About iCardiac Technologies:
iCardiac Technologies, Inc. is a technologically differentiated cardiac core lab providing expert scientific consultation, end-to-end project management, statistical analysis and the industry's most sophisticated FDA-accepted cardiac safety assessment methodologies. iCardiac's analysis service provides drug developers with more precise and cost-effective methods for QT interval measurement, including Highly Automated QT, which has been validated by pharmaceutical companies and accepted by the FDA as equivalent to the manual evaluation of ECGs in Thorough QT studies. In addition, iCardiac provides Beyond QT, a suite of advanced ECG-based cardiac safety markers that have been accepted as secondary end-points by the regulators, and deliver a more accurate assessment of the cardiac safety profile of drugs in development. iCardiac's COMPAS technology has been used for over a decade in cardiac clinical trials conducted for and by leading large and medium sized pharmaceutical, biotechnology, and medical device companies. For more information, visit: www.icardiac.com.

###

Read the full story at http://www.prweb.com/releases/false_positives/cardiac_safety/prweb2365904.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Cord Blood America Sees Significant Positives in President Obamas Lifting of Stem Cell Funding Restrictions
2. BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytrens Disease
3. Informex Survey Shows Innovation Remains a Priority for 2009 and Beyond
4. FDA Accepts Cell Therapeutics Zevalin sBLA and Grants Priority Review
5. FDA Issues Draft Guidance on Priority Review Vouchers
6. Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
7. Genta Restructures Operations to Focus on Priority Initiatives
8. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
9. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
10. The Journal of Cardiac Failure Publishes Results From Celladon Corporations First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure
11. iCardiac Applies Advanced Cardiac Safety Biomarkers in Clinical Study for Top Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back ... 8th June 2018 in San Francisco, CA. The Summit brings together current and former ... CEOs, board directors and government officials from around the world to address key issues ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are the ... million people each year. Especially those living in larger cities are affected by air ... one of the most pollution-affected countries globally - decided to take action. , “I ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that ... Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los ...
(Date:10/10/2017)... SANTA CRUZ, Calif. , Oct. 10, 2017 /PRNewswire/ ... SBIR grant from the NIH to develop RealSeq®-SC (Single ... preparation kit for profiling small RNAs (including microRNAs) from ... Cell Analysis Program highlights the need to accelerate development ... "New techniques for ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
Breaking Biology News(10 mins):